Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Repost from RB re: TSRG & IOAG
By: tesla2 $
Reply To: None Monday, 18 Jun 2001 at 3:18 PM EDT
Post # of 64146
New Info on TSRG and IOAG.....
I talked to Ike at OTC Financial Network and he provided me with this info:
Q..
Will the joint venture continue to drill more wells ? is IOAG involved in these projects. I thought there were plans for five or more .
A. YES, The company is currently working on multiple drilling programs, details will be announced soon.
How soon are we to expect West Virginia J/V with TSRG to begin seismic or date of operation to begin ?
A. TransEnergy is currently accepting bids for the seismic shoot, we should be updating the shareholders soon.
What is the future for relishing for the OTC Board ?
A. International is currently in the final steps of a full 2 year audit as required for the registration statement to the OTCBB and SEC, filings should be made by the 3rd Qtr.
Volumes for IOAG are nil what plans do you have to introduce IOAG to public awareness ?
A. The company has hired several PR groups with NFC spearheading the campaign, additional reports and other media programs will be introduced throughout the balance of the year.
I also asked the follwing information.
As a current investor in both IOAG and TSRG I am curious if there is a updated schedule as to when IOAG will be working up in West Virginia? Things appear to be heating up in that area in regards to gas explorations. What is IOAG plans for this area? I wish to invest additional monies but would like to get a better picture of IOAG's plan of attack.
Thanks in advance for any help you can give me.
International is currently evaluting the prospect for drilling of a test well before the end of the year. We expect to have the seismic program complete by the end of August, if the indications are what we expect and structure can be identified then we will start a 1-3 well program to further test the 6000 acre holdings.
In the interim, several drilling programs for the Hood County, Texas gas field and the Nevada Wake-up the Sleeping Giant project will be conducted.
Infotopia Responds to Volume/Price Issues; Infotopia Poised to File Lawsuit Against 'Bashers'
THURSDAY, JUNE 14, 2001 9:20 AM
- BusinessWire
BOSTON, Jun 14, 2001 (BUSINESS WIRE) -- Infotopia, Inc. (OTC:IFTP), today announced that it will file the lawsuit within next week against the internet "bashers" who have been providing false information through Internet Message Boards. The Company feels that this misleading information has had a direct effect on the share price of Infotopia's common stock.
Daniel Hoyng, Chairman and CEO of Infotopia stated, " The amount of calls and emails coming into our corporate offices by concerned shareholders over recent volatility of Infotopia's common stock and questions about the Company's stability has left the Company with little alternative but to defend its good name. We have received many calls concerning the share price and market valuation of Infotopia. Let me say this with absolute certainty, Infotopia is not now, nor has it ever been, in danger of failing. We, as a company, are more financially viable than we have ever been, our negotiations with EntrePort have been progressing nicely, and our products and infomercials are exceeding our expectations. A number of the issues that have been raised by these shareholders' emails and phone calls stem from the "basher" elements on the various Internet message boards. The fact is, as a company, we've never been better or stronger. Many shareholders fail to realize that this share pricing is a direct result of supply and demand, when shares are sold or shorted, which, we feel has historically been practiced, that effectively increases supply, if demand does not increase as well, price falls. The stock price falls, that's all, and it does not affect the profits and losses of the Company. Inherently, as a bulletin board company, we are at the mercy of the trading prices set by market makers. These market makers at times want a low stock price and at other times a high stock price, these "swings" help create volume and thus "profits" for these market makers. It's funny to me that as a profitable, fully reporting, public company, we have a market valuation that is less than the revenue derived from operations over a period of less than a month. That is a big factor in our decision to make the move to the AMEX market. We feel that we will be given a much more fair valuation, and have the opportunity to draw from the institutional support that will be made available to the Company."
Ernie Zavoral, President of Infotopia stated, "If you take the time to read over the past several press releases from the Company, you'll see that we continue to increase our revenues and profits, and we have three infomercials ranked in the top TEN in the entire country! That's an objective rarely accomplished in the Direct Response Industry. Our negotiations with EntrePort in securing a value more favorable to our shareholders are progressing well, and the flow of exciting new products and shows are exploding. It is imperative our shareholders, vendors, employees understand that Infotopia, is financially sound and poised to continue to grow and prosper well into the future."
ABOUT INFOTOPIA
The Company's mission is to produce, market, and distribute an expanding line of high-quality, innovative health, fitness and consumer products. Infotopia seeks out products that deliver superior value, outstanding quality, and competitive prices to best satisfy customer demand. The Company markets its products to consumers through a variety marketing channels, including infomercials, distributor alliances, and Internet e-commerce. The management at Infotopia is committed to increasing corporate revenues and profits. The company's website is located at http://www.infotopia.tv.
This news release includes "forward-looking statements" that include risk and uncertainties. The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including without limitation the Company's ability to produce and market products and/or services and other risks detailed from time to time in their Company's reports filed with the Securities Exchange Commission.
CONTACT: Infotopia, Inc.
Robert Tilton
609-888-4111
IFTPIR@infotopia.tv
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: CONSUMER/HOUSEHOLD
LEGAL/LAW
MEDICAL
Hi Arch and Muelhead! Nice find there muel! Is it going to apply to be listed? BWWLE that is. Just got home from work. See most of the pennies are red today. Just my luck while I'm at school tomorrow in Orlando it will be a rally Friday. LOL. Any scoops I should know about? Isn't that something Arch? I asked you about the charting on HCEN and a R/S pr comes out. LOL. Good luck and Good trading. Looks like STGA is holding her own today despite the demize of others. Ha!
b/r 2desire
John, here's a look at HICS Chart. Post some dd for everyone if you can. Thanks. Looks like its hitting bottom. That's where we want them to make the most $$$$. Kudos!
b/r 2desire
http://stockcharts.com/def/servlet/SC.web?c=NRES,uu[h,a]dhcayimy[db][pd10,2!b20!b50!b200!f][vc60][iu...
NRES Looks like a great buying Opportunity!!!!! See Chart.
http://stockcharts.com/def/servlet/SC.web?c=NRES,uu[h,a]dhcayimy[db][pd10,2!b20!b50!b200!f][vc60][iu...
b/r 2desire
WEDNESDAY, JUNE 13, 2001 9:01 AM
- PRNewswire
YOUNGSTOWN, Ohio, Jun 13, 2001 /PRNewswire via COMTEX/ -- Phar-Mor, Inc. (Nasdaq:PMOR), the discount drugstore chain, today announced the opening of its new online store offering shoppers easy access to over 25,000 products. The online store (available at http://www.PharMorWebRx.com) is powered by HealthCentral.com (Nasdaq:HCEN), a leading supplier of healthcare e-commerce through WebRx.com, and health content through HealthCentral.com and RxList.com.
One of the most comprehensive drugstores on the Web today, PharMorWebRx.com offers shoppers over-the-counter, health and beauty, and personal care items along with vitamins, minerals and supplements. The store's consumer-friendly features include Specialty Stores that allow shoppers to find everyday products quickly, an automatic re-order feature that conveniently remembers shoppers' regular purchases, and an information center featuring more than 90 topics and the latest health news from Dr. Dean Edell.
"We're pleased to be able to offer our customers a redesigned online store that complements our retail locations," said David Schwartz, President and COO of Phar-Mor. "WebRx's e-commerce platform, together with Phar-Mor's retailing expertise, will allow us to deepen our relationship with our customers by offering them the products and information they need to make Phar-Mor an even bigger part of their lives."
"Phar-Mor customers will benefit greatly from the wide variety of products, cost savings and convenience that WebRx offers," said Fred Toney, CEO and President of HealthCentral, the parent company of WebRx. "We look forward to providing them with premium service and selection."
PharMorWebRx.com will be promoted on PharMor.com, Phar-Mor's corporate Web site. PharMor.com also features Phar-Mor's complete online prescription service, answers to popular pharmacy and vitamin questions, and other consumer-friendly news and health care information. The revamped Web site reflects Phar-Mor's commitment to offering its customers the most convenient drugstore online and up-to-date, accurate health information. New features include:
* PillBot.com, an unbiased database that allows shoppers to easily
find and compare prices for hundreds of prescription drugs.
Phar-Mor's E-Pharmacy will match the lowest U.S. pharmacy price on
any drug or medication and delivers directly to consumers in
47 states.
* "Ask Our Pharmacist," an online area designed to help consumers get
professional, confidential answers to their prescription drug and
health questions, and "Ask our Vitamin Specialist," which allows
consumers to get answers to questions about nutritional supplements
and other vitamin-related questions.
* Phar-Mor Lens, the convenient, online store for contact lens and
lens care supplies.
* Visitors to PharMor.com can search for company-wide employment
opportunities and submit applications for jobs electronically.
Phar-Mor will aggressively market the new online store and revamped Web site in ad circulars and throughout the Phar-Mor retail network. The Company will feature the new URL on prescription and shopping bags, receipts, in-store signage, and in promotions on its in-store radio network.
About HealthCentral
HealthCentral (Nasdaq:HCEN) is a leading provider of healthcare e-commerce to consumers through WebRx(SM), a network of sites representing the consolidation of Vitamins.com, HealthCentral.com, RxList.com and others. Its e-commerce site, WebRx(SM) (http://www.webrx.com), features more than 25,000 products. WebRx(SM) features one of the largest on-line selections of vitamins, a Vision Center and a Comfort Living department (http://www.comfortliving.com) with a broad range of products including maternity and baby care, ergonomic chairs, water purifiers and an extensive line of allergy control products. HealthCentral.com (http://www.healthcentral.com) provides health-related information and commentary by Dr. Dean Edell, MD and other experts. RxList.com (http://www.rxlist.com) provides both patient-focused and professional-focused prescription drug information monographs.
About Phar-Mor
Phar-Mor is a retail drug store chain operating 139 stores under the names "Phar-Mor", "Pharmhouse" and "The Rx Place" in 24 states. The Company's common stock is traded on the Nasdaq National Market under the symbol "PMOR." Phar-Mor's online store is accessible at http://www.pharmorwebrx.com and through the Company's Web site at http://www.pharmor.com.
This release contains statements relating to future results of Phar-Mor, Inc. and its market share in the industry (including certain projections and business trends) that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to, market acceptance of merchandising concepts, changes in political and economic conditions, demand for and market acceptance of new and existing products, availability of new products, increased competition as well as other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.
CONTACTS:
Phar-Mor HealthCentral
Brian Browdie Melanie Hilario
212-484-7490 510-250-3806
MAKE YOUR OPINION COUNT -- Click Here
http://tbutton.prnewswire.com/prn/11690X65233459
SOURCE Phar-Mor, Inc.
CONTACT: Brian Browdie of Phar-Mor, 212-484-7490; or Melanie Hilario of
HealthCentral, 510-250-3806
URL: http://www.PharMorWebRx.com
http://www.prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
Repost of yesterday's SMXT NEWS!
http://www.bigcharts.com/news/articles.asp?newsid=780914595&orig=symbol&time=&symb=SMXT&...
Repost from RB WPTE
By: Nasdaq60 $$$
Reply To: 5317 by Nasdaq60 $$$ Thursday, 14 Jun 2001 at 1:48 AM EDT
Post # of 5330
JOINT VENT. AGREEMENT TO DEVELOP A ''GIANT OIL FIELD''
This project appears to have all the parameters when fully developed, to become a production property of Giant status, which would impact World Markets.''
http://ragingbull.lycos.com/mboard/boards.cgi?board=WPTE&read=5212
The strength of WesPac's management team stems from a
combination of years of experience and expertise in;
managerial, financial and technical areas.
In addition, the leadership and alignment characteristics of the executive management team are poised to take advantage of the current economic conditions in the oil and gas industry to effect a progressive and rapid fiscal growth of the Company.
Director and Executive Officer
Mr. Tettleton,
served as both Geophysicist and Manager for
Exxon Company USA
for over 15 years overseeing projects in
Texas, Mississippi,
Louisiana, Arkansas,
West Virginia, Kentucky and Libya.
Following Exxon,
Mr. Tettleton
was Vice-President of
Campbell Energy Corporation;
a joint-venture company specializing in the
Gulf Coast of South Louisiana with ventures partners such as Texaco
and Delhi Exploration.
He is President and Founder of
Gyro Exploration.
a joint venture
company specializing
in exploratory drilling in the South Louisiana Miocene
prolific producing trend.
He was a member of
The Society of Exploration Geophysicists International, member and
former Director of
The Baton Rouge Geological Society and Formerly District
Representative, District 3, SEG International.
Mr. Tettleton
received his B.S.
in Geology at Midwestern University.
Terrence A. Tecco,
President -
Mr. Tecco served as
President of
Olympic Resource Company, Inc.,
which focused on the acquisition of Gulf Coast producing properties with
major emphasis on South Louisiana.
As Vice-President of
Buckhorn Oil Company,
an independent exploration and production company operating out of
Houston, Texas and Ohio.
Mr. Tecco was responsible for the drilling of over 150 gas and oil wells in
Louisiana, Ohio,
Mississippi and Texas.
In addition, he supervised negotiations;
purchases,
pipeline transports and
investor relations.
Mr. Tecco represented
RieChad, USA, Inc.
a Canadian-based company that focused on US oil and gas acquisitions,
drilling two major producing properties and participating in leases both
onshore and
offshore out of Peru.
Mr. Tecco has been the key element to many successful joint
ventures and mergers in the oil and gas industry, offering WesPac over
18 years of
experience in the field,
providing an alliance to the major oil companies for future
projects.
He is a past member of the
American Association of Petroleum Landmen.
His background includes experience in
the financial market
where he held series 7 & 22 licenses.
Mr. Tecco graduated from
Kent State University
where he received his B.S. in Finance
and attended
Ohio State University Business Graduate School.
WPTE *^*^*^*^*^ TECCO & TETTLETON *^*^*^*^*^ LONG TEAM
http://www.wespactech.com/management.htm
For additional information, please contact
Tim Matula
Tel. 425-836-9035
or via email at
matula@cnw.com
http://www.wespactech.com/relations.htm
Oil & Gas Profiles.com/ WesPac Technologies, Corp. WPTE
http://www.pennystockportal.com/wpte/index.htm ;)
http://www.streetmarquee.com/WPTEfeatured.asp
http://www.blazinpicks.com/featured/wpte.htm
http://www.oilandgasprofiles.com/test/
http://www.investor-trading.com/profiles/WPTE.htm
http://www.microcapalliance.com/wpte.htm
Wespac Technologies Corp.
Mr.Terry Teccco - President
Phone: 972-987-5522
Email: Tecco6480@aol.com
P. O. Box 796841
Dallas, Texas 75379
Telephone (972) 377-9283
Fax (972) 377-8003
State of Incorporation: MN
Transfer Agents:
Signature Stock Transfer, Inc., Dallas, TX 75244
WPTE Well We Luv to Ride Y EOR Gusher Train*^*^*^*^*^
http://ragingbull.lycos.com/mboard/boards.cgi?board=WPTE&read=5315
http://ragingbull.lycos.com/mboard/boards.cgi?board=WPTE&read=5212
http://www.eia.doe.gov/emeu/cabs/guatemal.html#OIL
TIA Pass It Along *^*^*^*^*^*^*^*^
WESPAC TECHNOLOGIES CORP. PURCHASES WELLS IN SOUTH TEXAS
DALLAS--(BUSINESS WIRE)--June 14, 2001--
WesPac Technologies Corp. (OTC
Pink Sheets:WPTE) has purchased the Hamby Unit in Jones County, Texas containing 16 wells on 120 acres.
The field is currently cash flowing $7,500 a month with only four (4) wells partially in production.
WesPac will immediately begin a re-working program on the entire field.
Within thirty (30) days WesPac expects production of approximately 75 Barrels of oil per day, providing a net cash flow of $50,000 per month.
Total recoverable oil reserves are estimated to be 400,000 barrels for a total reserve value of ten million dollars ($10,000,000).
WesPac Technologies Corp. is a domestic oil and gas exploration, production, acquisition and service company based in Dallas, Texas.
WesPac has extended its operating footprint in North and South America and has adopted an aggressive acquisitions strategy to emerge as one of North America's leading regional oil and gas drilling, recovery and production companies.
For information please contact
WesPac's Investor Relations Agent and Consultant,
Tim Matula,
Matula 425/836-9035
or via e-mail matula@cnw.com.
This news release contains forward-looking statements relating to
future revenues and operating information and their impact on future
results. Actual results could differ materially from those projected in
forwarded-looking statements as a result of risk factors such as
availability of sufficient capital on terms to the company, market
conditions, technology shifts, the usual difficulty in introducing a new
product and the uncertainty of market conditions.
Contact:
Matula & Associates
Tim Matula, 425/836-9035
matula@cnw.com
---
http://www.wespactech.com
Oil & Gas Profiles.com/ WesPac Technologies, Corp.
WPTE
Sarals, I don't think it has anything to do w/ the market today. The Sixer's and Lakers are duking it out tonight. LOL.
2desire
NEWS OUT O37Point9 Announces Acquisition of Unique Health Care Services Company
(Business Wire 06/13/01 06:34:37)
Business Editors
LAS VEGAS--(BUSINESS WIRE)--June 13, 2001--37Point9 (OTCBB:TSPN)
announced today that it has signed a memo of understanding to acquire
the privately held CERNO HOLDINGS Limited, INC.
CERNO Holdings Limited, Inc, a Nevada Corporation, will be
acquired through a stock purchase transaction. CERNO is led by Charles
Kallmann, former Chairman of Hydrogiene Corporation (OTCBB:HICS). This
acquisition is the result of negotiations between the two companies to
use the Internet sales capacity of UPWEGO.com, an Internet retailer.
CERNO brings to the company the unique personal hygiene bidet
products known as the UB-the Ultimate Bidet as well as the soon to be
Patent Pending Medigiene product. These products, as well as a
variety of unique skin care products will be sold through UPWEGO.com
as well as using a Joint Venture with International Marketing
Consortium (IMC) of Jenkinstown, PA.
Legal Notice Regarding Forward-Looking Statements:
"Forward-looking statements" as defined in the Private Securities
Litigation Reform Act of 1995 may be included in this news release.
These statements relate to future events or our future financial
performance. These statements are only predictions and may differ
materially from actual future results or events. 37Point9 disclaims
any intention or obligation to revise any forward-looking statements
whether as a result of new information, future developments or
otherwise. There are important risk factors that could cause actual
results to differ from those contained in forward-looking statements,
including, but not limited to risks associated with changes in general
economic and business conditions, actions of our competitors, the
extent to which we are able to develop new services and markets for
our services, the time and expense involved in such development
activities, the level of demand and market acceptance of our services
and changes in our business strategies.
--30--crd/sf*
CONTACT: 37Point9
Doug Brown, 619/222-2568
Fax: 509/461-5818
KEYWORD: NEVADA
INDUSTRY KEYWORD: CONSUMER/HOUSEHOLD MERGERS/ACQ
Welcome Sarals! You've added alot to the boards. Congrats on directorship. If Muelhead and Arch vouch for you, I know your'e good! Good Luck w/ your trading.
2desire
Good Day Arch & Muel. Worked late. Saw the market tanked. Tomorrow, maybe, it will improve. EONE looks like a great pick Arch! There is alot happening on the OTCBB lately. I think its catching the eye of many who want to make a quick buck causing volatility in some stocks. Not complaining. Just makes things a little more exciting. Take care. Talk Later.
2desire
Arch, SMXT moved up .12 yesterday! FWIW. WTG Junglrulz!
2desire
MSEV News!
http://biz.yahoo.com/bw/010612/0487.html
b/r 2desire
Mangosoft DD
10QSB: MANGOSOFT INC
http://www.bigcharts.com/news/articles.asp?newsid=779156337&orig=symbol&time=&symb=MNGX&...
News releases
http://www.bigcharts.com/news/symbolnews.asp?symb=mngx&lookup=1&orig=symbol&x=13&y=1...
technical analysis
http://www.smallcapcenter.com/snapshot_techanalysis.asp?ticker=MNGX
Good trading all! :) I better get to bed. lol.
2desire
37Point9 Announces Signing of Letter of Intent to Merge
http://www.bigcharts.com/news/articles.asp?newsid=777194722&orig=symbol&time=&symb=TSPN&....
37Point9 Receives 5 Million Dollar Funding Agreement
http://www.bigcharts.com/news/articles.asp?newsid=777261654&orig=symbol&time=&symb=TSPN&....
10KSB: 37POINT9
http://www.bigcharts.com/news/articles.asp?newsid=777963971&orig=symbol&time=&symb=TSPN&...
I don't think this move is over yet. :)
2desire
Take a look at these gainers today.
http://www.clearstation.com/cgi-bin/drill_event?Event=PercGain&Refer=/index.html&Ordering=PP...
LOL! I lost track of it too. Just ran across it again tonight. It was a POW at one time. Ha!
2desire
By the way, Arch, KLYS Chart
http://stockcharts.com/def/servlet/SC.web?c=klys,uu[h,a]dhcayimy[db][pd10,2!b20!b50!b200!f][vc60][iu...
Looks like resistance is .03, If it breaks it could see .04 very soon.
2desire
Arch & Muel, Remember the stock I picked awhile back for the board tspn? Well we missed it. Went up 200% today on no news. :(
http://stockcharts.com/def/servlet/SC.web?c=tspn,uu[h,a]dhcayimy[db][pd10,2!b20!b50!b200!f][vc60][iu...
Muelhead, Take a look at this website!
http://www.eosbiotech.com/eos.html
b/r 2desire
Repost from RB re: STGA
By: eztradin $$$
Reply To: None Monday, 11 Jun 2001 at 5:15 PM EDT
Post # of 57638
The potential is this:
MKT. CAP: Only $288k
O/S: 55.4M
Float: 44.8M
Av. 10 day volume is 4.4M
Av. 3 day volume is 7.01M
With doing 6 mil. in sales(see news below)...
STGA would be a .11 stock; not including
their other business objectives which include
acquisitions.
See the potential here?
Saratoga International Announces Sales Revenue Forecast for Summer 2001 and Common Stock Recapitalization
KIRKLAND, Wash.--(BUSINESS WIRE)--March 30, 2001--Saratoga Telecom Inc., the telecommunications division of Saratoga International Holdings Corp. (OTCBB:SHCC - news), announced yesterday in an Internet CEO broadcast to interested investors that it is forecasting that activations of pre-paid long distance calling cards will reach $500,000 on a monthly basis, by the end of summer 2001.
This $6,000,000 of annualized activations is based on the competitive advantage offered by its newly commissioned VoIP platform.
Gene Retske, the president of Saratoga Telecom, said, ``We are very excited about the new platform. Many industry experts have predicted that VoIP will be the next major trend, not only in the prepaid calling card market, but in small business markets as well. We are proud to be one of the first to offer these services.
Do your DD. More to come.
EZ
STGA Business Summary
Saratoga International Holdings (Saratoga) is a development stage company whose strategy is to acquire and consolidate existing businesses and marketable technologies, products and services targeted at the e-commerce and telecommunications industry. The Company's subsidiary, Saratoga Telecom Corp., will market and sell virtual prepaid long distance telephone calling service over the Internet to customers who originate calls from foreign countries to the United States and to other foreign countries. Saratoga Telecom will also sell prepaid long distance telephone calling service over the Internet for calls originating in the United States to foreign countries and for long distance calls originating and terminating within the United States as well as calls originating in foreign countries to the United States and to other foreign countries. Saratoga's marketing plan also has been expanded to include selling prepaid long distance service hard cards in niche markets in the United States.
More from Market Guide: Expanded Business Description
Financial Summary
Saratoga International Holdings Corporation is a vertical growth internet and telecommunications facilitator specializing in penetrating low and mid-level market sectors. For the three months ended 1/31/01, revenues totalled $88 thousand, up from $7 thousand. Net loss applicable to Common rose 45% to $756 thousand. Revenues reflect the Company being in a developmental stage. Higher net loss reflects increased interest expense.
More from Market Guide: Significant Developments
Officers
FY1999 Pay
--------------------------------------------------------------------------------
Patrick Charles, 58
Pres, CEO, Director $146K
Tom Morsey, 52
Pres, Saratoga Telecom, Director 24K
Terrence Picken, 61
Exec. VP 146K
Dollar amounts are as of 31-Oct-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
STGA Business Summary
Saratoga International Holdings (Saratoga) is a development stage company whose strategy is to acquire and consolidate existing businesses and marketable technologies, products and services targeted at the e-commerce and telecommunications industry. The Company's subsidiary, Saratoga Telecom Corp., will market and sell virtual prepaid long distance telephone calling service over the Internet to customers who originate calls from foreign countries to the United States and to other foreign countries. Saratoga Telecom will also sell prepaid long distance telephone calling service over the Internet for calls originating in the United States to foreign countries and for long distance calls originating and terminating within the United States as well as calls originating in foreign countries to the United States and to other foreign countries. Saratoga's marketing plan also has been expanded to include selling prepaid long distance service hard cards in niche markets in the United States.
More from Market Guide: Expanded Business Description
Financial Summary
Saratoga International Holdings Corporation is a vertical growth internet and telecommunications facilitator specializing in penetrating low and mid-level market sectors. For the three months ended 1/31/01, revenues totalled $88 thousand, up from $7 thousand. Net loss applicable to Common rose 45% to $756 thousand. Revenues reflect the Company being in a developmental stage. Higher net loss reflects increased interest expense.
More from Market Guide: Significant Developments
Officers
FY1999 Pay
--------------------------------------------------------------------------------
Patrick Charles, 58
Pres, CEO, Director $146K
Tom Morsey, 52
Pres, Saratoga Telecom, Director 24K
Terrence Picken, 61
Exec. VP 146K
Dollar amounts are as of 31-Oct-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
Arch, You are welcome! Repost from RB re: STGA
By: eztradin $$$
Reply To: None Monday, 11 Jun 2001 at 5:15 PM EDT
Post # of 57638
The potential is this:
MKT. CAP: Only $288k
O/S: 55.4M
Float: 44.8M
Av. 10 day volume is 4.4M
Av. 3 day volume is 7.01M
With doing 6 mil. in sales(see news below)...
STGA would be a .11 stock; not including
their other business objectives which include
acquisitions.
See the potential here?
Saratoga International Announces Sales Revenue Forecast for Summer 2001 and Common Stock Recapitalization
KIRKLAND, Wash.--(BUSINESS WIRE)--March 30, 2001--Saratoga Telecom Inc., the telecommunications division of Saratoga International Holdings Corp. (OTCBB:SHCC - news), announced yesterday in an Internet CEO broadcast to interested investors that it is forecasting that activations of pre-paid long distance calling cards will reach $500,000 on a monthly basis, by the end of summer 2001.
This $6,000,000 of annualized activations is based on the competitive advantage offered by its newly commissioned VoIP platform.
Gene Retske, the president of Saratoga Telecom, said, ``We are very excited about the new platform. Many industry experts have predicted that VoIP will be the next major trend, not only in the prepaid calling card market, but in small business markets as well. We are proud to be one of the first to offer these services.
Do your DD. More to come.
EZ
AVN DD links per xxrayeyes.....
AVN DD Links:
Business Description
Avanir Pharmaceuticals is an emerging specialty pharmaceuticals and antibody generation services company engaged in the discovery, development and licensing of therapeutic products to treat chronic human diseases. In July 2000, the United States Food and Drug Administration approved the new drug application for the Company's lead therapeutic product, docosanol 10% cream, a topical treatment for recurrent oral-facial herpes infections, commonly known as cold sores and fever blisters. SmithKline Beecham began manufacturing and distributing docosanol 10% cream for the Company in the United States under the trade name Abreva in October 2000 under an exclusive license agreement for the North American market.
Expanded Business Description
http://yahoo.marketguide.com/mgi/busidesc.asp?rt=busidesc&rn=A0437
Significant Developments
http://yahoo.marketguide.com/mgi/signdevt.asp?rt=signdevt&rn=A0437
General Information and Share Information
http://biz.yahoo.com/p/a/avn.ob.html
Stock Report
http://www.amex.com/asp/quotes_reports.asp?symbol=AVN%60&selected=AVN%60
BigCharts Interactive Chart
http://www.bigcharts.com/intchart/frames/frames.asp?symb=avn&time=8&freq=1
SEC Filings
http://www.amex.com/asp/quotes_sec.asp?symbol=AVN%60&selected=AVN%60
Recent Press Releases
http://biz.yahoo.com/n/a/avn.ob.html
Company Webpage
http://www.avanir.com
Executive Biographies
http://yahoo.marketguide.com/mgi/biograph.asp?rt=biograph&rn=A0437
Insider Trade Data
http://biz.yahoo.com/t/a/avn.html
Top Institutional Holders
http://biz.yahoo.com/hd/a/avn.html
Short Interest
http://www.amex.com/asp/quotes_full.asp?kind=shortint&symbol=AVN%60&selected=AVN%60
Catalysts
http://moneycentral.msn.com/investor/research/wizards/srwcatalysts.asp?Symbol=avn
Historical Quotes
http://host.wallstreetcity.com/wsc2/Historical_Quotes.html?Button=NEW+REQUEST&template=hisquote.....
BarCharts Signals
http://quotes.barchart.com/texpert.asp?sym=avn
Stockscores.com Rating
http://www.stockscores.com/index.asp
AMEX Most Active List
http://www.amex.com/dynamic/marketactivityamex.htm#share
Technical Analysis Education
http://www.stockcharts.com/education/index.html
http://www.e-analytics.com/techdir.htm
http://www.chartpatterns.com
http://www.clearstation.com/education/cover.shtml
http://www.litwick.com
http://www.investormall.com/compleat/averages.htm
Charting Webpages
http://www.bigcharts.com
http://www.prophetcharts.com
http://www.stockcharts.com
SEC Complaint Link
http://www.sec.gov/enforce/comctr.html
AVN dd. Just passed its 200 MA for the second time in a month. Looks like a good stock. Worth keeping an eye on if you don't want to buy just yet. Reposted this dd from RB site. Good Luck.
2desire
Here's a nice look at the chart:
http://stockcharts.com/def/servlet/SC.web?c=avn,uu[h,a]dhcayimy[db][pd10,2!b20!b50!b200!f][vc60][iut....
UPDATE 6/06/01. Research link and why I invest in AVN. If you think more info belongs, let me know. New Investors here are the links to START your research. Good luck and do your DD.
http://www.avanir.com/whatsnew/press.cfm
1)5/14/01 $1.3 million in revenue from product Launch!!
http://www.bigcharts.com/news/articles.asp?newsid=779207888&symb=AVN&sid=126446
2) First six months remain profitable, earning one cent per share,compared to a loss of 14 cents for the same period a year ago. (same link above)
3) Two QUARTERS of PROFITS. FIRST TIME EVER!
a) http://www.bigcharts.com/news/articles.asp?newsid=747758064&symb=AVN&sid=126446
b) http://www.bigcharts.com/news/articles.asp?newsid=770483929&symb=AVN&sid=126446
4) ONLY FDA Approved drug for Cold Sores cream.
http://bigcharts.com/news/articles.asp?newsid=489758159&orig=&time=&symb=AVN&sid =126446&source=htx\http2_mw
5) Marketing partners with one of the world's biggest pharm companies (SMITHKLINE) for just N.America marketing rights alone. www.abreva.com (BY SmithKline)
11/29/00 OFFICIAL PRESS RELEASE!!!
http://www.bigcharts.com/news/articles.asp?newsid=730179183&symb=AVN&sid=126446
6) Smith Kline PAID AVN $ 25,000,000 milestone/upfront payment for the cream with Royalty payments in high single digit. ($15 million already)
http://bigcharts.com/news/articles.asp?newsid=732034002&orig=&time=&symb=AVN&sid =126446&source=htx\http2_mw
7)Abreva Herpes Cream selling OTC in Canada! Update!!
http://www.bigcharts.com/news/articles.asp?newsid=617424423&orig=symbol&time=&sy mb=AVN&sid=126446&source=htx\http2_mw
3/29/01 UPDATE: "Additionally, our New Drug Submission (NDS) with the Canadian Therapeutic Products Programme (TPP) was accepted for review early this year. GlaxoSmithKline will begin marketing Abreva™ in Canada when the product is approved for marketing."
8)Revenues from herpes cream royalties. STILL TO COME! GSK says: "GlaxoSmithKline is very pleased with results to date," said David W. Van Brunt, Marketing Director at GlaxoSmithKline Consumer Healthcare. "Consumer trial and sales have met early expectations. Each week the product is gaining distribution and continues to grow market share."
9)Marketing RIGHTS TO EUROPE AND ASIA STILL TO COME! They turned down GSK.
3/29/01 Update: "In addition to GlaxoSmithKline we have two existing partners, CTS Chemical Industries in Israel and Boryung Pharmaceuticals in South Korea. CTS and Boryung have initiated the pre-regulatory approval process in each of those respective countries. We have also been meeting with potential partners for Europe and Japan. Efforts to date include a recent trip to Japan for discussions with several leading Japanese consumer healthcare companies regarding the Japanese market."
10)NIH SBIR Grant to Study Novel Combination Therapy for Herpes Infections
http://bigcharts.com/news/articles.asp?newsid=492985560&orig=&time=&symb=AVN&sid =126446&source=htx\http2_mw
11) Other possible application for Docosanol once they get money or partners (see recent 10k)
"Possible Additional Uses of Docosanol 10% Cream. In addition to the potential marketing and sale of docosanol 10% cream as an OTC product for cold sores, other preclinical and clinical studies indicate that docosanol 10% cream may have other therapeutic properties that could open other avenues for product development. Potential indications for docosanol 10% cream include its use as a
topical treatment for genital herpes, Kaposi's sarcoma cutaneous lesions in HIV-positive patients, wound healing and minor burns. However, at present, we do not intend to continue development of any other potential topical indications, unless we obtain substantial additional funding or a development partner to share in the product development risks and cost of clinical trials."
http://www.sec.gov/Archives/edgar/data/858803/000109581100005452/0001095811-00-0 05452.txt
Then AVN has Xenerex which AVN owns 95%.
1) 6/06/01 UPDATE. AVN License patent for grafting adult human stem cells into SCID mice
http://www.bigcharts.com/news/articles.asp?newsid=780344015&symb=AVN&sid=126446
2) The official announcement that AVN has SCID mice. (with Patents 2/12/01 update)
DONE. 5/8/01 UPDATE.
http://www.bigcharts.com/news/articles.asp?newsid=769898323&symb=AVN&sid=126446
Xenerex Biosciences’s intellectual property platform resides in a series of patents to generate completely human antibodies of high affinity and specificity to a wide array of antigenic disease targets or human proteins. The two original patents (U.S. patent 5,698,767 and U.S. patent 5,476,996) are based on the pioneering work of Donald Mosier, M.D., Ph.D. and current Member of the Department of Immunology at The Scripps Research Institute in La Jolla, California. These patents claim the grafting of human lymphoid cells into Severe Combined Immmunodeficient (SCID) mice, for the purpose of studying various aspects of the human immune system outside the human body as well as the generation of completely human antibodies. These patents were extended by U.S. Patent 5,958,765, based on the work of Dr. Phillip Morrow, a founding scientist at Xenerex, and co-workers, that claim methods for generating human monoclonal antibodies using improved human cell sources and immunization procedures.
3) A "FASTER" & "CHEAPER" MOUSE
"Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human antibodies faster and cheaper than its competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody
Technology plc, Hansen said. "
Bioworld Online,
Aug 21, 2000
4)Oct 03, 2000 02:23 PM ET
By Donna Balancia, LOCALbusiness .com
"On Aug. 15, Avanir Pharmaceuticals announced the formation of a subsidiary called Xenerex Biosciences, a company that focuses on the area of monoclonal antibody research.
Wall Street looks positively on monoclonal antibody research. The FDA has fast-tracked approval on drugs relating to the use of antibodies and the market is potentially quite large, given the range of illnesses resulting from immune-related diseases, including cancer and AIDS.
Xenerex Biosciences will compete with Annandale, N.J.-based Medarex Inc. (Nasdaq: MEDX) and Abgenix Inc. (Nasdaq: ABGX) of Fremont, Calif., two firms that have a combined market share of almost $8 billion, in the lucrative antibody field."
5)"monomouse" partnerships and Acquires Patent.,
http://biz.yahoo.com/prnews/010212/ca_avanir_.html
6) Less outstanding shares than competitors MEDX & ABGX as of 4/9/01.
ABGX 82,409,000 shares
MEDX 72,258,000
AVN 57,306,002
http://www.bigcharts.com/quickchart/qsymbinfo.asp?sid=126446&time=8&freq=1&symb=avn
7)Review the scientific Board member for Xenorex.
XENEREX BIOSCIENCES FORMS SCIENTIFIC ADVISORY BOARD
San Diego, November 7, 2000 -
8)IgE for allergies & asthma
3/6/01 PATENT ALLOWANCE ISSUED!
"SAN DIEGO, March 6 /PRNewswire/ -- Avanir Pharmaceuticals announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for claims relating to a method of regulating production of immunoglobulin epsilon (IgE), a primary contributor to the symptoms of allergy and asthma. Avanir's preclinical research in this area is targeting a novel method of treating allergy and asthma through modulating the body's synthesis of IgE."
"The objective of our research program is to identify a novel small molecule compound capable of regulating IgE that can be taken orally for the treatment of allergies and asthma; however, our program is still in a substantially earlier preclinical stage of development...we have screened and identified several active candidate compounds that appear to be significantly selective and specific in their inhibition of the IgE antibody responses to allergens. From these compounds, we are attempting to identify therapeutic drug candidates for allergic disease therapy that will be active when ingested.
Other reasons I bought AVN.
1) AVP 923 UPDATE!!!
4/10/01 PATENT UPDATE!
http://www.bigcharts.com/news/articles.asp?newsid=777781769&symb=AVN&sid=126446
12/20/00 Enters Phase ii/III trials
http://www.bigcharts.com/news/articles.asp?newsid=747961293&symb=AVN&sid=126446
2)Granite Financial initiates coverage on AVN.
http://www.bigcharts.com/news/articles.asp?newsid=714346225&orig=charting&time=8 &symb=AVN&sid=126446&source=htx\http2_mw
3) Tax Loss Carry Forward
"We have provided a valuation allowance against the net deferred tax assets recorded as of September 30, 2000 and 1999 due to uncertainties as to their ultimate realization. The net operating loss and research credit
carryforwards expire through 2015. In the event of certain ownership changes, the Tax Reform Act of 1986 imposes certain restrictions on the amount of net operating loss carryforwards, which we may use in any year. As of September 30, 2000, we had $64,988,762 and $16,275,336 of federal and California net operating loss carryforwards, respectively."
from AVN's 10k
4) Increased institutional interest!!!
http://www.lionshares.com/secmasdetails.cfm?SEARCH=symbol&CUSIP=05348P104&SID=DS UD001%206374232984912012000150201%20%20%20%20%20075A54614C3556DE1E8B1EDBE076C14D E&PID=&RIGHTS=LC%7CCM%2C15%7C1%2C15A26BD96E70185C824D3F9C96DB05D7
Arch, take a look at this one. STGA. Saratoga Brands. They import Italian Foods and Cheeses. Looks like they've bottomed. Could make a move this week. Here's the link to dd on RB.
http://ragingbull.lycos.com/mboard/boards.cgi?board=STGA&read=57369
b/r 2desire
AVN dd. Just passed its 200 MA for the second time in a month. Looks like a good stock. Worth keeping an eye on if you don't want to buy just yet. Reposted this dd from RB site. Good Luck.
2desire
Here's a nice look at the chart:
http://stockcharts.com/def/servlet/SC.web?c=avn,uu[h,a]dhcayimy[db][pd10,2!b20!b50!b200!f][vc60][iut...
UPDATE 6/06/01. Research link and why I invest in AVN. If you think more info belongs, let me know. New Investors here are the links to START your research. Good luck and do your DD.
http://www.avanir.com/whatsnew/press.cfm
1)5/14/01 $1.3 million in revenue from product Launch!!
http://www.bigcharts.com/news/articles.asp?newsid=779207888&symb=AVN&sid=126446
2) First six months remain profitable, earning one cent per share,compared to a loss of 14 cents for the same period a year ago. (same link above)
3) Two QUARTERS of PROFITS. FIRST TIME EVER!
a) http://www.bigcharts.com/news/articles.asp?newsid=747758064&symb=AVN&sid=126446
b) http://www.bigcharts.com/news/articles.asp?newsid=770483929&symb=AVN&sid=126446
4) ONLY FDA Approved drug for Cold Sores cream.
http://bigcharts.com/news/articles.asp?newsid=489758159&orig=&time=&symb=AVN&sid =126446&source=htx\http2_mw
5) Marketing partners with one of the world's biggest pharm companies (SMITHKLINE) for just N.America marketing rights alone. www.abreva.com (BY SmithKline)
11/29/00 OFFICIAL PRESS RELEASE!!!
http://www.bigcharts.com/news/articles.asp?newsid=730179183&symb=AVN&sid=126446
6) Smith Kline PAID AVN $ 25,000,000 milestone/upfront payment for the cream with Royalty payments in high single digit. ($15 million already)
http://bigcharts.com/news/articles.asp?newsid=732034002&orig=&time=&symb=AVN&sid =126446&source=htx\http2_mw
7)Abreva Herpes Cream selling OTC in Canada! Update!!
http://www.bigcharts.com/news/articles.asp?newsid=617424423&orig=symbol&time=&sy mb=AVN&sid=126446&source=htx\http2_mw
3/29/01 UPDATE: "Additionally, our New Drug Submission (NDS) with the Canadian Therapeutic Products Programme (TPP) was accepted for review early this year. GlaxoSmithKline will begin marketing Abreva™ in Canada when the product is approved for marketing."
8)Revenues from herpes cream royalties. STILL TO COME! GSK says: "GlaxoSmithKline is very pleased with results to date," said David W. Van Brunt, Marketing Director at GlaxoSmithKline Consumer Healthcare. "Consumer trial and sales have met early expectations. Each week the product is gaining distribution and continues to grow market share."
9)Marketing RIGHTS TO EUROPE AND ASIA STILL TO COME! They turned down GSK.
3/29/01 Update: "In addition to GlaxoSmithKline we have two existing partners, CTS Chemical Industries in Israel and Boryung Pharmaceuticals in South Korea. CTS and Boryung have initiated the pre-regulatory approval process in each of those respective countries. We have also been meeting with potential partners for Europe and Japan. Efforts to date include a recent trip to Japan for discussions with several leading Japanese consumer healthcare companies regarding the Japanese market."
10)NIH SBIR Grant to Study Novel Combination Therapy for Herpes Infections
http://bigcharts.com/news/articles.asp?newsid=492985560&orig=&time=&symb=AVN&sid =126446&source=htx\http2_mw
11) Other possible application for Docosanol once they get money or partners (see recent 10k)
"Possible Additional Uses of Docosanol 10% Cream. In addition to the potential marketing and sale of docosanol 10% cream as an OTC product for cold sores, other preclinical and clinical studies indicate that docosanol 10% cream may have other therapeutic properties that could open other avenues for product development. Potential indications for docosanol 10% cream include its use as a
topical treatment for genital herpes, Kaposi's sarcoma cutaneous lesions in HIV-positive patients, wound healing and minor burns. However, at present, we do not intend to continue development of any other potential topical indications, unless we obtain substantial additional funding or a development partner to share in the product development risks and cost of clinical trials."
http://www.sec.gov/Archives/edgar/data/858803/000109581100005452/0001095811-00-0 05452.txt
Then AVN has Xenerex which AVN owns 95%.
1) 6/06/01 UPDATE. AVN License patent for grafting adult human stem cells into SCID mice
http://www.bigcharts.com/news/articles.asp?newsid=780344015&symb=AVN&sid=126446
2) The official announcement that AVN has SCID mice. (with Patents 2/12/01 update)
DONE. 5/8/01 UPDATE.
http://www.bigcharts.com/news/articles.asp?newsid=769898323&symb=AVN&sid=126446
Xenerex Biosciences’s intellectual property platform resides in a series of patents to generate completely human antibodies of high affinity and specificity to a wide array of antigenic disease targets or human proteins. The two original patents (U.S. patent 5,698,767 and U.S. patent 5,476,996) are based on the pioneering work of Donald Mosier, M.D., Ph.D. and current Member of the Department of Immunology at The Scripps Research Institute in La Jolla, California. These patents claim the grafting of human lymphoid cells into Severe Combined Immmunodeficient (SCID) mice, for the purpose of studying various aspects of the human immune system outside the human body as well as the generation of completely human antibodies. These patents were extended by U.S. Patent 5,958,765, based on the work of Dr. Phillip Morrow, a founding scientist at Xenerex, and co-workers, that claim methods for generating human monoclonal antibodies using improved human cell sources and immunization procedures.
3) A "FASTER" & "CHEAPER" MOUSE
"Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human antibodies faster and cheaper than its competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody
Technology plc, Hansen said. "
Bioworld Online,
Aug 21, 2000
4)Oct 03, 2000 02:23 PM ET
By Donna Balancia, LOCALbusiness .com
"On Aug. 15, Avanir Pharmaceuticals announced the formation of a subsidiary called Xenerex Biosciences, a company that focuses on the area of monoclonal antibody research.
Wall Street looks positively on monoclonal antibody research. The FDA has fast-tracked approval on drugs relating to the use of antibodies and the market is potentially quite large, given the range of illnesses resulting from immune-related diseases, including cancer and AIDS.
Xenerex Biosciences will compete with Annandale, N.J.-based Medarex Inc. (Nasdaq: MEDX) and Abgenix Inc. (Nasdaq: ABGX) of Fremont, Calif., two firms that have a combined market share of almost $8 billion, in the lucrative antibody field."
5)"monomouse" partnerships and Acquires Patent.,
http://biz.yahoo.com/prnews/010212/ca_avanir_.html
6) Less outstanding shares than competitors MEDX & ABGX as of 4/9/01.
ABGX 82,409,000 shares
MEDX 72,258,000
AVN 57,306,002
http://www.bigcharts.com/quickchart/qsymbinfo.asp?sid=126446&time=8&freq=1&symb=avn
7)Review the scientific Board member for Xenorex.
XENEREX BIOSCIENCES FORMS SCIENTIFIC ADVISORY BOARD
San Diego, November 7, 2000 -
8)IgE for allergies & asthma
3/6/01 PATENT ALLOWANCE ISSUED!
"SAN DIEGO, March 6 /PRNewswire/ -- Avanir Pharmaceuticals announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for claims relating to a method of regulating production of immunoglobulin epsilon (IgE), a primary contributor to the symptoms of allergy and asthma. Avanir's preclinical research in this area is targeting a novel method of treating allergy and asthma through modulating the body's synthesis of IgE."
"The objective of our research program is to identify a novel small molecule compound capable of regulating IgE that can be taken orally for the treatment of allergies and asthma; however, our program is still in a substantially earlier preclinical stage of development...we have screened and identified several active candidate compounds that appear to be significantly selective and specific in their inhibition of the IgE antibody responses to allergens. From these compounds, we are attempting to identify therapeutic drug candidates for allergic disease therapy that will be active when ingested.
Other reasons I bought AVN.
1) AVP 923 UPDATE!!!
4/10/01 PATENT UPDATE!
http://www.bigcharts.com/news/articles.asp?newsid=777781769&symb=AVN&sid=126446
12/20/00 Enters Phase ii/III trials
http://www.bigcharts.com/news/articles.asp?newsid=747961293&symb=AVN&sid=126446
2)Granite Financial initiates coverage on AVN.
http://www.bigcharts.com/news/articles.asp?newsid=714346225&orig=charting&time=8 &symb=AVN&sid=126446&source=htx\http2_mw
3) Tax Loss Carry Forward
"We have provided a valuation allowance against the net deferred tax assets recorded as of September 30, 2000 and 1999 due to uncertainties as to their ultimate realization. The net operating loss and research credit
carryforwards expire through 2015. In the event of certain ownership changes, the Tax Reform Act of 1986 imposes certain restrictions on the amount of net operating loss carryforwards, which we may use in any year. As of September 30, 2000, we had $64,988,762 and $16,275,336 of federal and California net operating loss carryforwards, respectively."
from AVN's 10k
4) Increased institutional interest!!!
http://www.lionshares.com/secmasdetails.cfm?SEARCH=symbol&CUSIP=05348P104&SID=DS UD001%206374232984912012000150201%20%20%20%20%20075A54614C3556DE1E8B1EDBE076C14D E&PID=&RIGHTS=LC%7CCM%2C15%7C1%2C15A26BD96E70185C824D3F9C96DB05D7
A repost from RB re: TSRG & IOAG
By: alamaniac $$$
Reply To: None Sunday, 10 Jun 2001 at 8:48 PM EDT
Post # of 63733
ON FRONT PAGE OF Oil.com
Getting good coverage this weekend>
International Oil and Gas continues to develop the exploration program for the West Virginia Gas Project in joint venture with Trans Energy, Inc. (OTC Bulletin Board: TSRG) and Jayhawk Resources Inc.
(IOAG PLM. TSRG)
Also in the Houston Chronicle newspaper.
Rod
Repost from RB re: TSRG & IOAG
By: alamaniac $$$
Reply To: None Sunday, 10 Jun 2001 at 8:48 PM EDT
Post # of 63733
ON FRONT PAGE OF Oil.com
Getting good coverage this weekend>
International Oil and Gas continues to develop the exploration program for the West Virginia Gas Project in joint venture with Trans Energy, Inc. (OTC Bulletin Board: TSRG) and Jayhawk Resources Inc.
(IOAG PLM. TSRG)
Also in the Houston Chronicle newspaper.
Rod
Here are some technicals on it.... Thanks again.
2desire
http://www.smallcapcenter.com/snapshot_techanalysis.asp?component=compinfo.asp&row=2&page=sn...
Josh, When you get a chance can you put together a dd page for AVN? They just crossed their 200 MA. TIA.
2desire
Keep an eye on IOAG this week. JV w/ TSRG. Repost from RB below.
By: candlestic $$$$
Reply To: None Sunday, 10 Jun 2001 at 12:42 PM EDT
Post # of 63715
After doing volume and price analysis on IOAG, I have come to the following conclusions.
(1) There are positive events unfolding in addition to those already announced.
(2) The volume theory number has increased to a positive number from a negative number. This has taken place as the daily price has gone down. It indicates major accumulation beginning to take place.
(3) You should determine in your own mind how this will affect the price of TSRG stock.
(4) A strong buy signal has been generated at Fridays closing price in IOAG stock.
Here are the Daily Price and Volume Numbers for IOAG going back to June of last year.
Date Open High Low Close Volume
06/08/01 0.220 0.300 0.220 0.300 52,500 + 29,015 buy
06/07/01 0.250 0.250 0.250 - 23,485
06/06/01 0.250 0.250 0.250 0.250 3,200 - 23,485
06/05/01 0.240 0.250 0.240 0.250 31,000 - 23,485
06/04/01 0.240 0.250 0.240 0.250 92,500 - 54,485
06/01/01 0.270 0.270 0.250 0.250 20,000 - 146.985
05/31/01 0.300 0.300 0.300 - 126,985
05/30/01 0.260 0.300 0.260 0.300 14,000 - 126,985
05/29/01 0.300 0.300 0.300 - 140,985
05/25/01 0.300 0.300 0.270 0.300 17,100 - 140,985
05/24/01 0.280 0.280 0.280 0.280 8,500 - 140,985
05/23/01 0.410 0.410 0.400 0.410 4,100 - 140,985
05/22/01 0.310 0.310 0.310 0.310 2,700 - 140,985
05/21/01 0.350 0.360 0.300 0.310 42,500 - 140,985
05/18/01 0.350 0.350 0.350 - 112,652
05/17/01 0.350 0.350 0.350 - 112,652
05/16/01 0.350 0.350 0.350 0.350 10,000 - 112,652
05/15/01 0.270 0.410 0.270 0.410 30,000 - 112,652
05/14/01 0.400 0.400 0.400 - 142,652
05/11/01 0.400 0.400 0.400 0.400 5,000 - 142,652
05/10/01 0.330 0.400 0.330 0.400 17,000 - 142,652
05/09/01 0.350 0.390 0.350 0.390 6,000 - 159,652
05/08/01 0.400 0.500 0.390 0.390 54,000 - 165,652
05/07/01 0.330 0.330 0.330 - 160,743
05/04/01 0.350 0.350 0.300 0.330 36,000 - 160,743
05/03/01 0.330 0.330 0.330 0.330 4,000 - 146,343
05/02/01 0.400 0.400 0.330 0.330 5,200 - 146,343
05/01/01 0.390 0.390 0.390 - 141,143
04/30/01 0.400 0.400 0.390 0.390 5,400 - 141,143
04/27/01 0.350 0.400 0.350 0.400 15,000 - 135,743
04/26/01 0.450 0.450 0.350 0.350 22,500 - 150,743
04/25/01 0.450 0.450 0.450 - 128,243
04/24/01 0.450 0.450 0.250 0.450 7,300 - 128,243
04/23/01 0.450 0.450 0.450 - 128,243
04/20/01 0.250 0.450 0.250 0.450 1,100 - 128,243
04/19/01 0.450 0.450 0.450 0.450 5,000 - 129,343
04/18/01 0.230 0.350 0.230 0.350 5,100 - 129,343
04/17/01 0.230 0.350 0.230 0.350 35,000 - 134,443
04/16/01 0.430 0.430 0.430 - 169,443
04/12/01 0.430 0.430 0.430 0.430 1,000 - 169,443
04/11/01 0.430 0.430 0.430 0.430 100 - 169,443
04/10/01 0.230 0.230 0.230 - 169,443
04/09/01 0.230 0.230 0.230 - 169,443
04/06/01 0.230 0.230 0.230 0.230 100 - 169,443
04/05/01 0.250 0.430 0.250 0.250 9,500 - 169,443
04/04/01 0.250 0.250 0.250 0.250 1,000 - 169,443
04/03/01 0.330 0.330 0.330 - 169,443
04/02/01 0.330 0.330 0.330 - 169,443
03/30/01 0.330 0.360 0.330 0.330 8,200 - 169,443
03/29/01 0.370 0.370 0.370 0.370 5,000 - 169,443
03/28/01 0.350 0.400 0.350 0.400 20,000 - 169,443
03/27/01 0.480 0.480 0.480 - 189,443
03/26/01 0.480 0.480 0.480 - 189,443
03/23/01 0.480 0.480 0.480 - 189,443
03/22/01 0.480 0.480 0.480 0.480 6,000 - 189,443
03/21/01 0.480 0.480 0.480 - 189,443
03/20/01 0.480 0.480 0.480 0.480 800 - 189,443
03/19/01 0.480 0.480 0.480 - 189,443
03/16/01 0.480 0.480 0.480 0.480 5,000 - 189,443
03/15/01 0.350 0.350 0.350 - 189,443
03/14/01 0.350 0.350 0.350 - 189,443
03/13/01 0.350 0.350 0.350 0.350 200 - 189,443
03/12/01 0.330 0.330 0.330 0.330 300 - 189,443
03/09/01 0.330 0.330 0.330 - 189,443
03/08/01 0.330 0.330 0.330 0.330 5,000 - 189,443
03/07/01 0.420 0.420 0.420 - 189,443
03/06/01 0.420 0.420 0.420 - 189,443
03/05/01 0.420 0.420 0.420 - 189,443
03/02/01 0.420 0.420 0.420 - 189,443
03/01/01 0.420 0.420 0.420 - 189,443
02/28/01 0.450 0.450 0.420 0.420 14,500 - 189,443
02/27/01 0.420 0.420 0.420 0.420 400 - 144,943
02/26/01 0.480 0.480 0.480 0.480 11,000 - 144,943
02/23/01 0.480 0.480 0.420 0.480 15,100 - 144,943
02/22/01 0.480 0.480 0.480 0.480 4,500 - 144,943
02/21/01 0.430 0.500 0.430 0.480 43,700 - 144,943
02/20/01 0.500 0.500 0.500 - 176,158
02/16/01 0.430 0.500 0.430 0.500 15,000 - 176,158
02/15/01 0.430 0.430 0.430 - 191,158
02/14/01 0.430 0.430 0.430 0.430 5,700 - 191,158
02/13/01 0.380 0.650 0.380 0.450 11,200 - 191,158
02/12/01 0.600 0.600 0.500 0.500 25,700 - 194,062
02/09/01 0.450 0.550 0.450 0.550 11,200 - 168,362
02/08/01 0.450 0.450 0.450 - 179,562
02/07/01 0.550 0.550 0.450 0.450 8,700 - 179,562
02/06/01 0.500 0.550 0.450 0.500 18,100 - 170,862
02/05/01 0.250 0.250 0.250 - 170,862
02/02/01 0.250 0.250 0.250 0.250 200 - 170,862
02/01/01 0.350 0.350 0.350 0.350 1,500 - 170,862
01/31/01 0.350 0.350 0.350 0.350 100 - 170,862
01/30/01 0.400 0.400 0.400 - 170,862
01/29/01 0.400 0.400 0.350 0.400 30,000 - 170,862
01/26/01 0.500 0.500 0.200 0.200 1,700 - 170,862
01/25/01 0.500 0.500 0.200 0.500 7,600 - 169,162
01/24/01 0.500 0.500 0.500 - 169,162
01/23/01 0.500 0.500 0.500 0.500 2,400 - 169,162
01/22/01 0.500 0.500 0.500 0.500 1,000 - 169,162
01/19/01 0.500 0.500 0.500 0.500 700 - 169,162
01/18/01 0.200 0.500 0.200 0.500 4,000 - 169,162
01/17/01 0.200 0.300 0.200 0.250 10,800 - 173,162
01/16/01 0.500 0.500 0.200 0.200 1,800 - 178,562
01/12/01 0.500 0.500 0.200 0.200 1,300 - 176,762
01/11/01 0.250 0.250 0.250 - 175,462
01/10/01 0.250 0.250 0.250 - 175,462
01/09/01 0.250 0.250 0.250 - 175,462
01/08/01 0.400 0.400 0.250 0.250 2,800 - 175,642
01/05/01 0.300 0.300 0.250 0.250 7,000 - 172,842
01/04/01 0.150 0.150 0.150 0.150 300 - 165,842****
01/03/01 0.350 0.350 0.200 0.250 29,000 - 165,842
01/02/01 0.350 0.350 0.350 0.350 2,000 - 146,509
12/29/00 0.350 0.350 0.350 0.350 3,100 - 146,509
12/28/00 0.200 0.450 0.100 0.100 57,200 - 146,509****
12/27/00 0.200 0.250 0.200 0.250 1,300 - 130,167
12/26/00 0.300 0.300 0.200 0.200 6,500 - 131,467
12/22/00 0.300 0.300 0.300 - 124,967
12/21/00 0.350 0.350 0.250 0.300 39,000 - 124,967
12/20/00 0.300 0.300 0.300 0.300 800 - 105,467
12/19/00 0.350 0.350 0.350 - 105,467
12/18/00 0.350 0.350 0.350 - 105,467
12/15/00 0.350 0.350 0.350 - 105,467
12/14/00 0.550 0.550 0.350 0.350 2,300 - 105,467
12/13/00 0.350 0.350 0.350 0.350 2,500 - 103,167
12/12/00 0.520 0.520 0.520 - 103,167
12/11/00 0.300 0.520 0.300 0.520 2,700 - 103,167
12/08/00 0.300 0.300 0.300 0.300 500 - 105,867
12/07/00 0.500 0.500 0.500 - 105,867
12/06/00 0.450 0.500 0.450 0.500 10,000 - 105,867
12/05/00 0.500 0.500 0.500 0.500 8,400 - 115,867
12/04/00 0.450 0.450 0.450 0.450 1,100 - 115,867
12/01/00 0.550 0.550 0.300 0.450 12,800 - 115,867
11/30/00 0.300 0.350 0.250 0.350 16,000 - 110,717
11/29/00 0.700 0.700 0.400 0.400 39,500 - 118,717
11/28/00 0.600 0.600 0.350 0.370 111,200 - 79,217
11/27/00 0.660 0.660 0.500 0.500 37,000 + 23,087
11/24/00 0.600 0.600 0.600 + 60,087
11/22/00 0.620 0.620 0.600 0.600 5,400 + 60,087
11/21/00 0.700 0.700 0.650 0.650 8,000 + 65,487
11/20/00 0.750 0.750 0.650 0.650 11,100 + 73,487
11/17/00 0.850 0.850 0.850 0.850 4,800 + 84,587
11/16/00 0.750 0.750 0.750 0.750 1,200 + 84,587
11/15/00 0.770 0.770 0.770 0.770 4,900 + 84,587
11/14/00 0.770 0.770 0.770 0.770 1,000 + 84,587
11/13/00 0.840 0.840 0.840 0.840 4,500 + 84,587
11/10/00 0.840 0.840 0.840 0.840 2,500 + 84,587
11/09/00 0.850 0.850 0.840 0.840 7,500 + 84,587
11/08/00 0.920 0.920 0.830 0.830 31,200 + 91,587sell
11/07/00 0.890 0.890 0.800 0.890 61,100 + 122,787
11/06/00 0.800 0.890 0.750 0.890 35,900 + 122,787
11/03/00 0.750 0.800 0.750 0.800 28,900 + 99,709
11/02/00 0.750 0.900 0.700 0.850 100,300 + 70,809
11/01/00 0.750 0.750 0.700 0.700 26,000 + 20,659
10/31/00 0.700 0.700 0.700 + 46,659
10/30/00 0.600 0.730 0.600 0.700 6,400 + 46,659
10/27/00 0.750 0.750 0.750 + 41,736
10/26/00 0.750 0.750 0.750 + 41,736
10/25/00 0.750 0.750 0.750 0.750 2,700 + 41,736
10/24/00 0.700 0.750 0.600 0.750 19,000 + 41,736
10/23/00 0.690 0.690 0.690 0.690 5,000 + 35,403
10/20/00 0.550 0.650 0.550 0.650 7,600 + 35,403
10/19/00 0.700 0.750 0.450 0.610 57,000 + 27,803
10/18/00 0.750 0.750 0.750 + 44,903
10/17/00 0.600 0.750 0.600 0.750 400 + 44,903
10/16/00 0.650 0.650 0.550 0.650 2,400 + 44,503
10/13/00 0.350 0.625 0.350 0.600 47,000 + 44,503Buy
10/12/00 0.350 0.750 0.350 0.750 38,800 + 1,776
10/11/00 0.700 0.700 0.700 - 36,024
10/10/00 0.700 0.700 0.700 0.700 4,700 - 36,024
10/09/00 0.700 0.700 0.700 - 36,024
10/06/00 0.700 0.700 0.700 - 36,024
10/05/00 0.550 0.700 0.550 0.700 6,000 - 36,024
10/04/00 0.600 0.600 0.530 0.530 7,200 - 42,024
10/03/00 0.600 0.600 0.600 - 35,024
10/02/00 0.600 0.600 0.600 0.600 1,100 - 35,024
09/29/00 0.600 0.600 0.600 - 35,024
09/28/00 0.650 0.650 0.530 0.600 4,200 - 35,024
09/27/00 0.530 0.630 0.530 0.630 2,500 - 33,274
09/26/00 0.600 0.600 0.600 - 35,774
09/25/00 0.600 0.600 0.600 0.600 14,000 - 35,774
09/22/00 0.600 0.640 0.600 0.640 6,600 - 35,774
09/21/00 0.600 0.600 0.600 0.600 2,500 - 42,374
09/20/00 0.600 0.650 0.600 0.620 6,200 - 42,374
09/19/00 0.600 0.600 0.600 0.600 1,000 - 44,854
09/18/00 0.680 0.680 0.680 - 44,854
09/15/00 0.600 0.680 0.600 0.680 3,500 - 44,854
09/14/00 0.750 0.750 0.600 0.600 8,000 - 48,354
09/13/00 0.750 0.750 0.700 0.700 9,500 - 40,354
09/12/00 0.750 0.750 0.750 - 30,854
09/11/00 0.750 0.750 0.750 0.750 13,300 - 30,854
09/08/00 0.680 0.680 0.600 0.600 12,100 - 30,854
09/07/00 0.680 0.680 0.680 0.680 100 - 18,754
09/06/00 0.600 0.650 0.600 0.650 14,300 - 18,754
09/05/00 0.600 0.600 0.600 0.600 2,500 - 33,054
09/01/00 0.680 0.680 0.600 0.600 4,000 - 33,054
08/31/00 0.750 0.750 0.600 0.680 2,600 - 29,054
08/30/00 0.700 0.750 0.700 0.750 11,500 - 28,041
08/29/00 0.600 0.750 0.600 0.750 3,800 - 39,541
08/28/00 0.680 0.750 0.650 0.750 32,800 - 43,341
08/25/00 0.750 0.750 0.700 0.700 20,000 - 66,301
08/24/00 0.650 0.750 0.600 0.700 134,600 - 46,301
08/23/00 0.750 0.750 0.600 0.600 52,700 - 91,168
08/22/00 0.800 0.812 0.750 0.750 92,300 - 48,468sell
08/21/00 0.700 1.000 0.625 0.750 107,600 + 25,967***
08/18/00 0.550 0.550 0.550 0.550 10,000 + 11,621
08/17/00 1.550 0.800 0.800 + 11,621
08/16/00 1.000 1.000 0.800 0.800 10,200 + 11,621***
08/15/00 1.000 1.000 1.000 1.000 1,000 + 21,821
08/14/00 0.950 0.950 0.950 0.950 100 + 21,821***
08/11/00 0.750 0.875 0.650 0.875 30,200 + 21,821
08/10/00 0.900 1.000 0.900 1.000 38,000 + 21,821***
08/09/00 0.750 0.975 0.750 0.880 46,400 - 16,179
08/08/00 0.250 0.950 0.250 0.950 2,700 - 42,988
08/07/00 0.950 0.950 0.950 0.950 200 - 45,582
08/04/00 1.550 0.750 0.750 - 45,582
08/03/00 1.550 0.750 0.750 - 45,582
08/02/00 1.550 0.750 0.750 - 45,582
08/01/00 1.550 0.750 0.750 - 45,582
07/31/00 0.850 0.900 0.750 0.750 17,200 - 45,582
07/28/00 0.880 0.900 0.850 0.850 7,500 - 34,116
07/27/00 1.550 0.800 0.900 - 29,616
07/26/00 0.900 0.900 0.880 0.900 28,100 - 29,616
07/25/00 0.900 0.900 0.900 0.900 11,200 - 29,616
07/24/00 0.950 0.950 0.950 0.950 2,000 - 29,616
07/21/00 1.550 0.800 0.950 - 29,616
07/20/00 1.050 1.050 0.800 0.950 13,400 - 29,616
07/19/00 1.550 0.800 1.120 - 20,683
07/18/00 1.550 0.750 1.120 - 20,683
07/17/00 1.550 0.750 1.120 - 20,683
07/14/00 1.550 0.800 1.120 - 20,683
07/13/00 1.125 1.125 1.120 1.120 300 - 20,683
07/12/00 1.000 1.000 0.850 0.850 900 - 20,383
07/11/00 1.000 1.000 0.800 0.800 16,200 - 19,483
07/10/00 0.800 1.062 0.800 1.000 13,000 - 3,283
07/07/00 1.550 0.900 0.900 - 13,207
07/06/00 0.900 0.900 0.900 0.900 1,000 - 13,207
07/05/00 1.080 1.100 0.900 1.000 24,600 - 13,207
07/03/00 1.300 1.300 1.080 1.080 1,200 - 3,367
06/30/00 1.150 1.250 1.060 1.200 56,200 - 2,167
06/29/00 1.150 1.150 1.150 1.150 2,500 - 16,957
06/28/00 1.100 1.100 1.060 1.100 12,200 - 16,957
06/27/00 1.312 1.350 1.050 1.100 5,600 - 16,957
06/26/00 1.450 1.550 1.050 1.050 25,500 - 13,000*****
06/23/00 1.400 1.400 1.125 1.125 3,500 + 7,400
06/22/00 1.310 1.450 1.310 1.450 3,400 + 10,900
06/21/00 1.280 1.312 1.280 1.312 7,500 + 7,500
06/20/00 1.280 1.280 1.280 1.280 300 0,000,000